News | 12 September 2026
Briefs: Senores Pharmaceuticals and KIMS
Senores subsidiary completes USFDA inspection for Vadodara facility
Senores subsidiary completes USFDA inspection for Vadodara facility
The Swiss affordable-medicines giant said its new Bio100 strategy will put biosimilars at the heart of its long-term expansion
The biggest investment—Rs 350 crore—will go toward a new, fully backward-integrated Ibuprofen manufacturing unit at IOLCP’s Barnala, Punjab facility
The launch advances company's respiratory innovation journey and reinforces continued progress in expanding access to differentiated therapies across global markets
Lonza said the Bend project will strengthen its ability to provide integrated, end-to-end development and manufacturing services for SDDs
13th edition of the event drew buyers from 128 countries and second Bharat Health Global Expo to be held from August 19–21, 2027
As per the company, no critical or major observations were made during the UK-MHRA current Good Manufacturing Practices (cGMP) inspection
The unannounced onsite USFDA bioequivalence inspection was conducted from 31st August, 2026 to 10th September, 2026
The new entity focused on development and commercial manufacturing services for complex molecules will operate separately from its parent company’s corporate identity
The company has positioned BugSpeaks as a non-diagnostic, wellness-focused test, rather than a tool for diagnosing or treating medical conditions.
The expansion will add four new GMP suites, taking the total number of suites at the site from six to 10
Nanopharm, Aptar Pharma’s specialist inhalation development services business, will lead formulation development and device assessment for ACT-101, supporting Aceso’s clinical development roadmap
Novartis India Limited has acquired the exclusive rights to promote and distribute NHPL's retina portfolio across India
This decision unlocks the opportunity to scale FPL’s established expertise in product development, manufacturing, and supply chain logistics directly into the pet-care industry
Renocia Exo offers a new multitargeted approach to hair loss management by supporting the biology of the hair follicle-not just hair growth
The buyback will be primarily funded through proceeds from Fosun Pharma’s disposal of approximately 6% of its equity stake in Gland Pharma, for total consideration of around US$294 million
Bhutan has recorded zero human deaths from dog-mediated rabies since June 2023
The technology targets some of the most difficult wounds to heal
Subscribe To Our Newsletter & Stay Updated
